Abstract
Prostaglandins (PGs) are involved in mediating or regulating many physiological as well as pathological processes. Important roles of PGs in the pathophysiology of carcinogenesis offer potentials of targeting PG synthesis and PG receptors in developing novel anti-cancer therapy. Although initial studies suggested direct growth inhibitory role of PGs from in vitro studies, it has been widely demonstrated that in general, PGs stimulate tumor growth. However, cyclopentenone PGs, especially 15d-PGJ2, which can activate peroxisome proliferator activated receptor (PPAR) γ, exhibited anti-proliferative and proapoptotic effects on many types of cancer cells. But recent studies indicate that growth inhibitory effects of the cyclopentenone PGs might also be a nonspecific effect due to its highly reactive cyclopentenone ring. We have explored the published studies on PGs to specify its known regulatory roles on tumor growth with an objective of targeting the PGs or pathways activated by these lipids in treating cancers.
Keywords: Prostaglandins, anti-cancer, cyclopentenone, peroxisome
Current Medicinal Chemistry - Anti-Cancer Agents
Title: Effect of Prostaglandins on the Regulation of Tumor Growth
Volume: 4 Issue: 4
Author(s): Shunji Ishihara, M A.K. Rumi, Toshihiko Okuyama and Yoshikazu Kinoshita
Affiliation:
Keywords: Prostaglandins, anti-cancer, cyclopentenone, peroxisome
Abstract: Prostaglandins (PGs) are involved in mediating or regulating many physiological as well as pathological processes. Important roles of PGs in the pathophysiology of carcinogenesis offer potentials of targeting PG synthesis and PG receptors in developing novel anti-cancer therapy. Although initial studies suggested direct growth inhibitory role of PGs from in vitro studies, it has been widely demonstrated that in general, PGs stimulate tumor growth. However, cyclopentenone PGs, especially 15d-PGJ2, which can activate peroxisome proliferator activated receptor (PPAR) γ, exhibited anti-proliferative and proapoptotic effects on many types of cancer cells. But recent studies indicate that growth inhibitory effects of the cyclopentenone PGs might also be a nonspecific effect due to its highly reactive cyclopentenone ring. We have explored the published studies on PGs to specify its known regulatory roles on tumor growth with an objective of targeting the PGs or pathways activated by these lipids in treating cancers.
Export Options
About this article
Cite this article as:
Ishihara Shunji, Rumi A.K. M, Okuyama Toshihiko and Kinoshita Yoshikazu, Effect of Prostaglandins on the Regulation of Tumor Growth, Current Medicinal Chemistry - Anti-Cancer Agents 2004; 4 (4) . https://dx.doi.org/10.2174/1568011043352902
DOI https://dx.doi.org/10.2174/1568011043352902 |
Print ISSN 1568-0118 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5968 |
Related Articles
-
A Brief Evaluation of Tumor Imaging in Mice with 99mTc-glucarate Including a Comparison with 18F-FDG
Current Radiopharmaceuticals Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design Medicinal Chemistry of Indolylglyoxylamide TSPO High Affinity Ligands with Anxiolytic-Like Effects
Current Topics in Medicinal Chemistry Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Anesthetic Cardioprotection in Relation to Mitochondria: Basic Science
Current Pharmaceutical Design IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry Expression and Function of Angiomodulating Cytokines in Rheumatoid Arthritis and Experimental Arthritis: Important Therapeutic Targets
Current Immunology Reviews (Discontinued) RNAi in Clinical Studies
Current Medicinal Chemistry The Targets of Curcumin
Current Drug Targets Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Antineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Current Pharmaceutical Design New Insights into the Chemistry and Antioxidant Activity of Coumarins
Current Topics in Medicinal Chemistry Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry